Covid Quick Update

COVID19 - CORONAVIRUS, 22 Feb 2021

Swiss Policy Research - TRANSCEND Media Service

16 Feb 2021 – Some quick covid updates on early treatment, face masks, vaccines, and more.

Vitamin D: Another Spanish prospective study with 930 hospitalized covid patients found that high-dose vitamin D (calcifediol) reduced ICU admissions by 80% and mortality by 60%.

Ivermectin 1: A large Indian prospective study with 3,500 health care workers found that just two doses of Ivermectin reduced the risk of infection over a one month period by 83%. This confirms the results of an earlier Argentinian study, which found that a weekly dose of ivermectin reduced the risk of covid infection by 100% in 1200 health care workers.

Ivermectin 2: An Israeli placebo-controlled, double-blinded randomized trial led by professor Eli Schwartz found a highly significant effect on viral clearance in 94 mostly young patients.

Face masks: The European CDC has updated its face mask policy recommendations. The ECDC acknowledges that after more than one year since the beginning of the pandemic, there is still no evidence supporting the effectiveness of medical and non-medical face masks in the community. Furthermore, the ECDC advises against the use of FFP2/N95 respirators by the general public. However, based on the ‘precautionary principle’, the ECDC does recommend the use of face masks in some situations and for some people.

Vaccines: Data from Israel confirms very high short-term effectiveness of the Pfizer mRNA vaccine. On the other hand, according to adverse events reporting systems in the US, the UK and the EU, there are now over 2,000 confirmed post-vaccination deaths. Israel’s main problem was that its vaccination campaign ran in parallel to its largest covid wave, producing many infections in partially vaccinated people, which could increase the risk of vaccine-escaping virus strains.

Down Under: After local outbreaks, Auckland and Melbourne are once again under lockdown.

USA: Drug overdoses increased by 45% in 2020, according to the CDC.

__________________________________________

Swiss Policy Research, founded in 2016, is an independent, nonpartisan and nonprofit research group investigating geopolitical propaganda in Swiss and international media. SPR is composed of independent academics that for personal and professional reasons prefer to protect their identities, and receives no external funding; there are no financial sponsors or backers. Our articles have been published or shared by numerous independent media outlets and journalists, among them Julian Assange, and have been translated into more than two dozen languages.

Go to Original – swprs.org


Tags: , , , , , , , , , , , , , , , , , , , , , , ,

 

Share this article:


DISCLAIMER: The statements, views and opinions expressed in pieces republished here are solely those of the authors and do not necessarily represent those of TMS. In accordance with title 17 U.S.C. section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. TMS has no affiliation whatsoever with the originator of this article nor is TMS endorsed or sponsored by the originator. “GO TO ORIGINAL” links are provided as a convenience to our readers and allow for verification of authenticity. However, as originating pages are often updated by their originating host sites, the versions posted may not match the versions our readers view when clicking the “GO TO ORIGINAL” links. This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.


There are no comments so far.

Join the discussion!

We welcome debate and dissent, but personal — ad hominem — attacks (on authors, other users or any individual), abuse and defamatory language will not be tolerated. Nor will we tolerate attempts to deliberately disrupt discussions. We aim to maintain an inviting space to focus on intelligent interactions and debates.

*

code

This site uses Akismet to reduce spam. Learn how your comment data is processed.